Author index of volume 53

Akanuma, Y., see Takahashi, Y. 53, 91

Apparao, C., see Kesavulu, M.M. 53, 33

Asahina, T., see Tanaka, Y. 53, 41

Assimakopoulos, D., V. Danielides, N. Kontogianis, A. Skevas, A. Tsatsoulis, Sudden hearing loss as the presenting symptom of diabetes mellitus 53, 201

Atkinson, A.B., see Wiggam, M.I. 53, 73

Atsumi, Y., see Tanaka, Y. 53, 41

Babaya, N., see Ueda, H. 53, 67

Bal, C.S., see Goswami, R. 53, 181

Bassili, A., M. Omar, G. Tognoni, The adequacy of diabetic care for children in a developing country 53, 187

Bell, P.M., see Wiggam, M.I. 53, 73

Blum, M., see Schiel, R. 53, 173

Broderick, T.L., see Felix, C. 53, 17

Broemeling, L.D., see Mielke, C.H. 53, 55

Bruce, D.G., N. Harrington, W.A. Davis, T.M.E. Davis, Dementia and its associations in type 2 diabetes mellitus: The Fremantle Diabetes Study 53, 165

Budd, S., see Gatling, W. 53, 107

Calle, J.R., see Calle-Pascual, A.L. 53, 129

Calle-Pascual, A.L., A. Durán, A. Diaz, G. Moñux, F.J. Serrano, N.G. de la Torre, I. Moraga, J.R. Calle, A. Charro, J.P. Marañes, Comparison of peripheral arterial reconstruction in diabetic and non-diabetic patients: a prospective clinic-based study 53, 129

Charro, A., see Calle-Pascual, A.L. 53, 129

Chou, J., see Okuda, Y. 53, 1

Cohen, C.N., F.M.A. Filho, M. de Fátima Gonçalves, M. de Brito Gomes, Early alterations of blood pressure in normotensive and normoalbuminuric Type 1 diabetic patients 53, 85

Coope, P.A., see Florkowski, C.M. 53, 113

Danielides, V., see Assimakopoulos, D. 53, 201 Davis, T.M.E., see Bruce, D.G. 53, 165 Davis, W.A., see Bruce, D.G. 53, 165 de Fátima Gonçalves, M., see Cohen, C.N. 53, 85 de la Torre, N.G., see Calle-Pascual, A.L. 53, 129 De Leeuw, I.H., see Van Gaal, L.F. 53, 141 Diaz, A., see Calle-Pascual, A.L. 53, 129 Driedzic, W.R., see Felix, C. 53, 17 Durán, A., see Calle-Pascual, A.L. 53, 129

de Brito Gomes, M., see Cohen, C.N. 53, 85

Dyer-Parziale, M., The effect of extend bar containing uncooked cornstarch on night-time glycemic excursion in subjects with type 2 diabetes 53, 137

Egusa, G., see Fujikawa, R. 53, 99 Ennis, C.N., see Wiggam, M.I. 53, 73

Felix, C., M. Gillis, W.R. Driedzic, D.J. Paulson, T.L. Broderick, Effects of propionyl-L-carnitine on isolated mitochondrial function in the reperfused diabetic rat heart 53, 17

Field, J.B., see Okuda, Y. 53, 1

Filho, F.M.A., see Cohen, C.N. 53, 85

Florkowski, C.M., R.S. Scott, P.A. Coope, C.L. Moir, Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study 53, 113

Fujikawa, R., M. Okubo, G. Egusa, N. Kohno, Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow up study 53, 99

Fujimoto, S., see Shen, Z.-P. 53, 9

Fujisawa, T., see Ueda, H. 53, 67

Fukushima, M., see Hiragushi, K. 53, 149

Gatling, W., R.N. Guzder, J.C. Turnbull, S. Budd, M.A. Mullee, The Poole Diabetes Study: how many cases of Type 2 diabetes are diagnosed each year during normal health care in a defined community? 53, 107

Gillis, M., see Felix, C. 53, 17

Giri, R., see Kesavulu, M.M. 53, 33

Goswami, R., C.S. Bal, S. Tejaswi, G.V. Punjabi, A. Kapil, N. Kochupillai, Prevalence of urinary tract infection and renal scars in patients with diabetes mellitus 53, 181

Goswami, R., N. Kochupillai, N. Gupta, A. Kukreja, M. Lan, N.K. Maclaren, Islet cell autoimmunity in youth onset diabetes mellitus in Northern India 53, 47

Greuter, H., see Lehmann, R. 53, 121 Gupta, N., see Goswami, R. 53, 47 Guzder, R.N., see Gatling, W. 53, 107

Harrington, N., see Bruce, D.G. 53, 165
Hiragushi, K., H. Sugimoto, K. Shikata, T. Yamashita, N. Miyatake, Y. Shikata, J. Wada, I. Kumagai, M. Fukushima, H. Makino, Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo- and micro-albuminuric patients with type 2 diabetes 53, 149

Höffken, K., see Schiel, R. 53, 173 Hosokawa, K., see Tanaka, Y. 53, 41 Hunter, S.J., see Wiggam, M.I. 53, 73

Ikegami, H., see Ueda, H. 53, 67 Iwamoto, Y., see Maruyama, S. 53, 161

Kademann, A., see Schiel, R. 53, 173 Kadowaki, T., see Takahashi, Y. 53, 91 Kanamuro, R., see Maruyama, S. 53, 161 Kapil, A., see Goswami, R. 53, 181 Kawaguchi, Y., see Ueda, H. 53, 67 Kawamori, R., see Tanaka, Y. 53, 41 Kayrooz, S., see Lehmann, R. 53, 121

Kesavulu, M.M., B.K. Rao, R. Giri, J. Vijaya, G. Subramanyam, C. Apparao, Lipid peroxidation and antioxidant enzyme status in Type 2 diabetics with coronary heart disease 53, 33

Kimura, S., see Takahashi, Y. 53, 91 Kochupillai, N., see Goswami, R. 53, 47 Kochupillai, N., see Goswami, R. 53, 181 Köhler, S., see Schiel, R. 53, 173 Kohno, N., see Fujikawa, R. 53, 99 Kontogianis, N., see Assimakopoulos, D. 53, 201 Kukreja, A., see Goswami, R. 53, 47 Kumagai, I., see Hiragushi, K. 53, 149 Kuzuya, T., see Takahashi, Y. 53, 91

Lan, M., see Goswami, R. 53, 47
Lehmann, R., S. Kayrooz, H. Greuter, G.A. Spinas, Clinical and technical evaluation of a new self-monitoring blood glucose meter: assessment of analytical and user error 53, 121

Maclaren, N.K., see Goswami, R. 53, 47
Makino, H., see Hiragushi, K. 53, 149
Marañes, J.P., see Calle-Pascual, A.L. 53, 129
Maruyama, S., K. Yanagisawa, R. Kanamuro, S. Teno, Y. Iwamoto, Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus 53, 161
Matsunaga, H., see Tanaka, Y. 53, 41
Matsuoka, K., see Tanaka, Y. 53, 41

Mielke, C.H., J.P. Shields, L.D. Broemeling, Coronary artery calcium, coronary artery disease, and diabetes 53, 55
Miyatake, N., see Hiragushi, K. 53, 149
Moir, C.L., see Florkowski, C.M. 53, 113
Mokubo, A., see Tanaka, Y. 53, 41
Moñux, G., see Calle-Pascual, A.L. 53, 129
Moraga, I., see Calle-Pascual, A.L. 53, 129
Mukai, E., see Shen, Z.-P. 53, 9
Mullee, M.A., see Gatling, W. 53, 107
Müller, U.A., see Schiel, R. 53, 173

Nishimura, M., see Shen, Z.-P. 53, 9 Noda, M., see Takahashi, Y. 53, 91 Nojima, K., see Ueda, H. 53, 67

Ogawa, O., see Tanaka, Y. 53, 41
Ogihara, T., see Ueda, H. 53, 67
Ohashi, Y., see Takahashi, Y. 53, 91
Okubo, M., see Fujikawa, R. 53, 99
Okuda, Y., J. Peña, J. Chou, J.B. Field, Acute effects of growth hormone on metabolism of pancreatic hormones, glucose and ketone bodies 53, 1

Paulson, D.J., see Felix, C. 53, 17 Peña, J., see Okuda, Y. 53, 1 Punjabi, G.V., see Goswami, R. 53, 181

Omar, M., see Bassili, A. 53, 187

Onuma, T., see Tanaka, Y. 53, 41

Rao, B.K., see Kesavulu, M.M. 53, 33 Richardson, C., see Simmons, R.W. 53, 25

Schiel, R., M. Blum, U.A. Müller, S. Köhler, A. Kademann, J. Strobel, K. Höffken, Screening for people with diabetes mellitus for poor blood glucose control in an ophthalmological laser clinic 53, 173

Scott, R.S., see Florkowski, C.M. 53, 113 Seino, Y., see Shen, Z.-P. 53, 9

Serrano, F.J., see Calle-Pascual, A.L. 53, 129

Shen, Z.-P., M. Nishimura, Y. Tsuura, S. Fujimoto, E. Mukai, Y. Yamada, Y. Seino, Distinct effect of diazoxide on insulin secretion stimulated by protein kinase A and protein kinase C in rat pancreatic islets 53, 9

Sheridan, B., see Wiggam, M.I. 53, 73 Shibata, M., see Ueda, H. 53, 67 Shields, J.P., see Mielke, C.H. 53, 55 Shikata, K., see Hiragushi, K. 53, 149 Shikata, Y., see Hiragushi, K. 53, 149

Shimada, S., see Tanaka, Y. 53, 41

Simmons, R.W., C. Richardson, The effects of muscle activation on postural stability in diabetes mellitus patients with cutaneous sensory deficit in the foot 53, 25

Skevas, A., see Assimakopoulos, D. 53, 201 Spinas, G.A., see Lehmann, R. 53, 121 Strobel, J., see Schiel, R. 53, 173

Subramanyam, G., see Kesavulu, M.M. 53, 33 Sugimoto, H., see Hiragushi, K. 53, 149 Takagi, M., see Tanaka, Y. 53, 41

Takahashi, Y., M. Noda, S. Tsugane, S. Kimura, Y. Akanuma, T. Kuzuya, Y. Ohashi, T. Kadowaki, Importance of standardization of hemoglobin A_{1c} in the analysis of factors that predict hemoglobin A_{1c} levels in non-diabetic residents of three distinct areas of Japan 53, 91

Tanaka, Y., Y. Atsumi, K. Matsuoka, A. Mokubo, T. Asahina, K. Hosokawa, S. Shimada, H. Matsunaga, M. Takagi, O. Ogawa, T. Onuma, R. Kawamori, Usefulness of stable HbA_{1c} for supportive marker to diagnose diabetes mellitus in Japanese subjects 53, 41

Tejaswi, S., see Goswami, R. 53, 181

Teno, S., see Maruyama, S. 53, 161

Tognoni, G., see Bassili, A. 53, 187

Tsatsoulis, A., see Assimakopoulos, D. 53, 201

Tsugane, S., see Takahashi, Y. 53, 91

Tsuura, Y., see Shen, Z.-P. 53, 9

Turnbull, J.C., see Gatling, W. 53, 107

Ueda, H., H. Ikegami, Y. Kawaguchi, T. Fujisawa, K. Nojima, N. Babaya, K. Yamada, M. Shibata, E. Yamato, T. Ogihara, Mapping and promoter sequencing of HNF-1β gene in diabetes-prone and -resistant mice 53, 67

Van Acker, K.L., see Van Gaal, L.F. 53, 141

Van Gaal, L.F., K.L. Van Acker, I.H. De Leeuw, Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes 53, 141

Vijaya, J., see Kesavulu, M.M. 53, 33

Wada, J., see Hiragushi, K. 53, 149

Wiggam, M.I., S.J. Hunter, C.N. Ennis, B. Sheridan, A.B. Atkinson, P.M. Bell, Insulin action and skeletal muscle blood flow in patients with Type 1 diabetes and microalbuminuria 53, 73

Yamada, K., see Ueda, H. 53, 67

Yamada, Y., see Shen, Z.-P. 53, 9

Yamashita, T., see Hiragushi, K. 53, 149

Yamato, E., see Ueda, H. 53, 67

Yanagisawa, K., see Maruyama, S. 53, 161





Diabetes Research and Clinical Practice 53 (2001) 209-212

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Subject index of volume 53

Albuminuria; Insulin resistance 53, 99

Ambulatory blood pressure monitoring; Normoalbuminuria; Type 1 diabetes **53**, 85

Analytical error; Self-monitoring blood glucose; Glucose meters; User error 53, 121

Antioxidant enzymes; (Non-)insulin-dependent diabetes mellitus [(N)IDDM]; Lipid peroxidation; Thiobarbituric acid reactive substances (TBARS); Coronary heart disease (CHD) 53, 33

Arterial reconstruction; Diabetes mellitus; Diabetic foot; Limb salvage; Neuropathy; Mortality **53**, 129

Cardiac function; Diabetes; Propionyl-L-carnitine; Mitochondria; Reperfusion 53, 17

Children; Type 1 diabetes mellitus; Quality of care; Developing countries; Egypt; Markers for chronic diabetic complications **53**, 187

Chromosome mapping; NSY mouse; *Tcf*2; HNF-1β; SNP; Promoter; Type 2 diabetes **53**, 67

Clinical types; Youth onset diabetes in tropics; Islet cell and thyroid autoimmunity markers; C-peptide response 53, 47

Cornstarch; Extend bar; Hyperglycemia; Hypoglycemia; Type 2 diabetes 53, 137

Coronary artery calcium; Coronary artery disease; Diabetes 53, 55

Coronary artery disease; Coronary artery calcium; Diabetes **53**, 55

Coronary heart disease (CHD); (Non-)insulin-dependent diabetes mellitus [(N)IDDM]; Lipid peroxidation; Thiobarbituric acid reactive substances (TBARS); Antioxidant enzymes 53, 33

C-peptide response; Youth onset diabetes in tropics; Clinical types; Islet cell and thyroid autoimmunity markers 53, 47

Cutaneous deficit; Electromyography; Response latencies; Diabetes 53, 25

Dementia; Type 2 diabetes mellitus; Old age; Hypertension **53**, 165

Developing countries; Type 1 diabetes mellitus; Children; Quality of care; Egypt; Markers for chronic diabetic complications **53**, 187

Diabetes; Coronary artery calcium; Coronary artery disease 53, 55

Diabetes; Electromyography; Response latencies; Cutaneous deficit 53, 25

Diabetes mellitus; Arterial reconstruction; Diabetic foot; Limb salvage; Neuropathy; Mortality 53, 129

Diabetes mellitus; Diagnostic criteria; Oral glucose tolerance test; Stable HbA_{1c} 53, 41

Diabetes mellitus; Non-insulin-dependent Type 2 diabetes; Epidemiology; Incidence; Diagnosis **53**, 107

Diabetes; Propionyl-L-carnitine; Mitochondria; Cardiac function; Reperfusion 53, 17

Diabetes; Urinary tract infections; 99m Technetium dimercapto-succinic acid 53, 181

Diabetic foot; Arterial reconstruction; Diabetes mellitus; Limb salvage; Neuropathy; Mortality 53, 129

Diabetic nephropathy; Glomerular hyperfiltration; Nitric oxide; Endothelial cell nitric oxide synthase; Type 2 diabetes 53, 149

Diabetic retinopathy; Type 1 diabetes mellitus; Type 2 diabetes mellitus; HbA_{1c}; Structured treatment and teaching programme 53, 173

Diagnosis; Diabetes mellitus; Non-insulin-dependent Type 2 diabetes; Epidemiology; Incidence 53, 107

Diagnostic criteria; Diabetes mellitus; Oral glucose tolerance test; Stable HbA_{1c} 53, 41

Diazoxide; Insulin secretion; Protein kinase A; Protein kinase C 53, 9

Egypt; Type 1 diabetes mellitus; Children; Quality of care; Developing countries; Markers for chronic diabetic complications **53**, 187

Electromyography; Response latencies; Diabetes; Cutaneous deficit **53**, 25

Endothelial cell nitric oxide synthase; Glomerular hyperfiltration; Nitric oxide; Diabetic nephropathy; Type 2 diabetes 53, 149

Epidemiology; Diabetes mellitus; Non-insulin-dependent Type 2 diabetes; Incidence; Diagnosis **53**, 107

Extend bar; Cornstarch; Hyperglycemia; Hypoglycemia; Type 2 diabetes 53, 137

Glomerular hyperfiltration; Nitric oxide; Endothelial cell nitric oxide synthase; Diabetic nephropathy; Type 2 diabetes 53, 149

Glucagon; Hepatic glucose; Insulin; Ketone body metabolism 53, 1

Glucose clamp technique; Type 1 diabetes; Microalbuminuria; Insulin resistance; Venous occlusion plethysmography **53**, 73

Glucose meters; Self-monitoring blood glucose; Analytical error; User error 53, 121

HbA_{1c}; Type 1 diabetes mellitus; Type 2 diabetes mellitus; Diabetic retinopathy; Structured treatment and teaching programme 53, 173

Hemoglobin A_{1c}; Standardization; HPLC; Immunochemical method 53, 91

Hepatic glucose; Glucagon; Insulin; Ketone body metabolism 53, 1

HNF-1β; NSY mouse; *Tcf2*; SNP; Promoter; Type 2 diabetes; Chromosome mapping **53**, 67

HPLC; Standardization; Hemoglobin A_{1c} ; Immunochemical method 53, 91

Hyperglycemia; Extend bar; Cornstarch; Hypoglycemia; Type 2 diabetes 53, 137

Hypertension; Type 2 diabetes mellitus; Dementia; Old age 53, 165

Hypoglycemia; Extend bar; Cornstarch; Hyperglycemia; Type 2 diabetes **53**, 137

Immunochemical method; Standardization; Hemoglobin A_{1c} ; HPLC 53, 91

Incidence; Diabetes mellitus; Non-insulin-dependent Type 2 diabetes; Epidemiology; Diagnosis **53**, 107

Insulin; Glucagon; Hepatic glucose; Ketone body metabolism 53, 1

Insulin resistance; Albuminuria 53, 99

Insulin resistance; Type 1 diabetes; Microalbuminuria; Glucose clamp technique; Venous occlusion plethysmography 53, 73

Insulin secretion; Diazoxide; Protein kinase A; Protein kinase C 53, 9

Islet cell and thyroid autoimmunity markers; Youth onset diabetes in tropics; Clinical types; C-peptide response 53, 47

Ketone body metabolism; Glucagon; Hepatic glucose; Insulin 53, 1

Leptin; Troglitazone; Type 2 diabetes 53, 161

Limb salvage; Arterial reconstruction; Diabetes mellitus; Diabetic foot; Neuropathy; Mortality 53, 129

Lipid peroxidation; (Non-)insulin-dependent diabetes mellitus [(N)IDDM]; Thiobarbituric acid reactive substances (TBARS); Antioxidant enzymes; Coronary heart disease (CHD) **53**, 33

Markers for chronic diabetic complications; Type 1 diabetes mellitus; Children; Quality of care; Developing countries; Egypt **53**, 187

Mealtime insulin secretion; Type 2 diabetes; Repaglinide; Oral hypoglycaemic agents; Prandial glucose regulation 53, 141

Microalbuminuria; Type 1 diabetes; Insulin resistance; Glucose clamp technique; Venous occlusion plethysmography 53, 73

Mitochondria; Diabetes; Propionyl-L-carnitine; Cardiac function; Reperfusion 53, 17

Mortality; Arterial reconstruction; Diabetes mellitus; Diabetic foot; Limb salvage; Neuropathy 53, 129

Mortality; Natural history; Type 2 diabetes 53, 113

99m Technetium dimercapto-succinic acid; Diabetes; Urinary tract infections **53**, 181

Natural history; Mortality; Type 2 diabetes 53, 113

Neuropathy; Arterial reconstruction; Diabetes mellitus; Diabetic foot; Limb salvage; Mortality 53, 129

Nitric oxide; Glomerular hyperfiltration; Endothelial cell nitric oxide synthase; Diabetic nephropathy; Type 2 diabetes **53**, 149

(Non-)insulin-dependent diabetes mellitus [(N)IDDM]; Lipid peroxidation; Thiobarbituric acid reactive substances (TBARS); Antioxidant enzymes; Coronary heart disease (CHD) 53, 33

Non-insulin-dependent Type 2 diabetes; Diabetes mellitus; Epidemiology; Incidence; Diagnosis 53, 107

Normoalbuminuria; Ambulatory blood pressure monitoring; Type 1 diabetes **53**, 85

NSY mouse; *Tcf*2; HNF-1β; SNP; Promoter; Type 2 diabetes; Chromosome mapping **53**, 67

Old age; Type 2 diabetes mellitus; Dementia; Hypertension 53, 165

Oral glucose tolerance test; Diabetes mellitus; Diagnostic criteria; Stable HbA_{1c} 53, 41

Oral hypoglycaemic agents; Type 2 diabetes; Repaglinide; Mealtime insulin secretion; Prandial glucose regulation 53, 141

Prandial glucose regulation; Type 2 diabetes; Repaglinide; Oral hypoglycaemic agents; Mealtime insulin secretion **53**, 141

Promoter; NSY mouse; *Tcf*2; HNF-1β; SNP; Type 2 diabetes; Chromosome mapping **53**, 67

Propionyl-L-carnitine; Diabetes; Mitochondria; Cardiac function; Reperfusion **53**, 17

Protein kinase A; Diazoxide; Insulin secretion; Protein kinase C 53, 9

Protein kinase C; Diazoxide; Insulin secretion; Protein kinase A 53, 9

Quality of care; Type 1 diabetes mellitus; Children; Developing countries; Egypt; Markers for chronic diabetic complications 53, 187

Repaglinide; Type 2 diabetes; Oral hypoglycaemic agents; Mealtime insulin secretion; Prandial glucose regulation 53, 141

Reperfusion; Diabetes; Propionyl-L-carnitine; Mitochondria; Cardiac function 53, 17

Response latencies; Electromyography; Diabetes; Cutaneous deficit **53**, 25

Self-monitoring blood glucose; Glucose meters; Analytical error; User error 53, 121

SNP; NSY mouse; *Tcf*2; HNF-1β; Promoter; Type 2 diabetes; Chromosome mapping 53, 67

Stable HbA_{1c}; Diabetes mellitus; Diagnostic criteria; Oral glucose tolerance test 53, 41

Standardization; Hemoglobin A_{1c} ; HPLC; Immunochemical method 53, 91

Structured treatment and teaching programme; Type 1 diabetes mellitus; Type 2 diabetes mellitus; Diabetic retinopathy; HbA_{1c} 53, 173

*Tcf***2**; NSY mouse; HNF-1β; SNP; Promoter; Type 2 diabetes; Chromosome mapping **53**, 67

Thiobarbituric acid reactive substances (TBARS); (Non-)insulin-dependent diabetes mellitus [(N)IDDM]; Lipid peroxidation; Antioxidant enzymes; Coronary heart disease (CHD) 53, 33

Troglitazone; Leptin; Type 2 diabetes 53, 161

Type 1 diabetes; Ambulatory blood pressure monitoring; Normoalbuminuria **53**, 85

Type 2 diabetes; Extend bar; Cornstarch; Hyperglycemia; Hypoglycemia **53**, 137

Type 2 diabetes; Glomerular hyperfiltration; Nitric oxide; Endothelial cell nitric oxide synthase; Diabetic nephropathy 53, 149

Type 2 diabetes; Leptin; Troglitazone 53, 161

Type 1 diabetes mellitus; Children; Quality of care; Developing countries; Egypt; Markers for chronic diabetic complications **53**, 187

Type 2 diabetes mellitus; Dementia; Old age; Hypertension 53, 165

Type 2 diabetes mellitus; Type 1 diabetes mellitus; Diabetic retinopathy; HbA_{1c}; Structured treatment and teaching programme 53, 173

Type 1 diabetes mellitus; Type 2 diabetes mellitus; Diabetic retinopathy; HbA_{1c}; Structured treatment and teaching programme **53**, 173

Type 1 diabetes; Microalbuminuria; Insulin resistance; Glucose clamp technique; Venous occlusion plethysmography **53**, 73

Type 2 diabetes; Mortality; Natural history 53, 113

Type 2 diabetes; NSY mouse; Tcf2; HNF-1β; SNP; Promoter;

Chromosome mapping 53, 67

Type 2 diabetes; Repaglinide; Oral hypoglycaemic agents; Mealtime insulin secretion; Prandial glucose regulation 53, 141

Urinary tract infections; Diabetes; 99m Technetium dimercapto-succinic acid 53, 181

User error; Self-monitoring blood glucose; Glucose meters; Analytical error 53, 121

Venous occlusion plethysmography; Type 1 diabetes; Microalbuminuria; Insulin resistance; Glucose clamp technique 53,

Youth onset diabetes in tropics; Clinical types; Islet cell and thyroid autoimmunity markers; C-peptide response 53, 47

